In this issue:
Discontinuing DMTs after disease inactivity in RRMS
Brain gadolinium accumulation after multiple MRI scans
Dalfampridine improves cognition in MS patients
Risk of natalizumab-associated PML with EID vs SID
The natalizumab wearing-off effect
Outcomes after pre-pregnancy discontinuation of DMTs
Symptomatology and symptomatic treatment in MS
Age is a critical determinant in recovery from MS relapses
Mindfulness-based interventions for mental well-being in MS patients
Oral ozanimod vs interferon beta-1a in RRMS
Please login below to download this issue (PDF)